BOT 1503 Study Analysis, page-12

"The primary endpoint for the Phase 2 Study measured an absolute change from baseline in inflammatory lesions at week 12. Secondary endpoints included: percent change from baseline in inflammatory lesions; absolute and percent change from baseline in non-inflammatory lesions; andthe proportion of patients achieving at least clear or almost clear and a 2-grade improvement from baseline (IGA Success) on the 5-grade Investigator’s Global Assessment (IGA) scale. Each endpoint was assessed at the end of the 12-week treatment period."